Quaero Life Was Approved to be Listed on the Sci-Tech Innovation Board

2022CACLP Booth No: B4-1304

On October 13, 2022, the Shenzhen Stock Exchange disclosed that the 73rd Review Meeting of the GEM Listing Committee in 2022 was held and approved Jiaxing Quaero Life Science Co., Ltd. to be listed on the Sci-Tech Innovation Board.

Quaero Life plans to raise 700 million CNY, the full name of the project is "Jiaxing Quaero Life-Technology Co., Ltd. is used for in vitro diagnostic instrument R&D project, and 150 million CNY is used to supplement working capital.

About Quaero:

Quaero Bio is a leading in vitro diagnostic instrument and life science consumables R&D and manufacturing company in China, providing customized products and services for in vitro diagnostic instruments and life science consumables, covering the whole life cycle of product development, design transformation, product registration, precision manufacturing and after-sales maintenance.

Headquartered in Jiaxing City, Zhejiang Province, Quaero has three R&D companies in Jiaxing, Shanghai and Hangzhou, with a standardized manufacturing plant, a GMP-compliant consumables plant and a wholly-owned subsidiary——Boyu Bio, it has a total area of 16,000 square meters. It is reported that after the successful re-election of Quaero Life, it is known as "the first stock of IVD instrument CDMO" in the industry.

The products of Quaero Life mainly include instruments and consumables, among which the instruments are mainly used in the fields of immunodiagnosis, microbiology diagnosis, pathology diagnosis, POCT, etc. They are custom developed according to the needs of in vitro diagnostic manufacturers, and the cooperative customers include Auto Bio, Tellgen, Joinstar… The consumables are mainly used in the operation of the instruments including conductive tips and non-conductive tips, reaction cups (tubes), reagent containers, etc., which are used in the operation of instruments.

According to the prospectus, the revenue of Quaero Life in 2019, 2020 and 2021 will be 132 million CNY, 259 million CNY and 573 million CNY respectively. The net profit will be 17.532 million CNY, 66.852 million CNY and 124 million CNY respectively. The net profit after deduction will be 15.8587 million CNY, 39.285 million CNY and 78.986 million CNY respectively.

Quaero 's revenue for the first half of 2022 is 269 million CNY, net profit is 45.567 million CNY, net profit after deduction is 28.199 million CNY. The revenue is expected to be 597 million to 716 million in 2022.